You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MEDI9447

Showing 1 - 19 of 19
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumors Trial in Australia, Korea, Republic of, United States (MEDI9447, MEDI9447 and MEDI4736)

Active, not recruiting
  • Solid Tumors
  • MEDI9447
  • MEDI9447 and MEDI4736
  • La Jolla, California
  • +17 more
Nov 21, 2022

Muscle Invasive Bladder Cancer Trial in Boston (Durvalumab, Oleclumab)

Completed
  • Muscle Invasive Bladder Cancer
  • Boston, Massachusetts
  • +1 more
Sep 8, 2022

Pancreatic Ductal Adenocarcinoma Trial in Toronto (Durvalumab, Oleclumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 22, 2023

Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 Trial

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +5 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

NSCLC Trial in Marseille (Durvalumab (MEDI4736), Monalizumab (IPH2201), Oleclumab (MEDI9447))

Recruiting
  • Non-small Cell Lung Cancer
  • Durvalumab (MEDI4736)
  • +5 more
  • Marseille, France
    Assistance Publique Hopitaux de Marseille
Sep 21, 2022

Triple Negative Breast Cancer Trial in Belgium, France (Paclitaxel, Carboplatin, MEDI4736)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Brussels, Belgium
  • +17 more
Feb 28, 2022

Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial in United States (AZD4635, Oleclumab, Durvalumab)

Active, not recruiting
Has Results
  • Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Denver, Colorado
  • +8 more
Jan 12, 2023

Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma Trial in Houston (Durvalumab,

Recruiting
  • Metastatic Angiosarcoma
  • +7 more
  • Durvalumab
  • Oleclumab
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2021

Ovarian Cancer Trial in Denmark, Finland, Norway (Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562)

Completed
  • Ovarian Cancer
  • Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
  • Vejle, Region Syddanmark, Denmark
  • +4 more
Jan 7, 2022

Non Small Cell Lung Cancer, Renal Cell Carcinoma Trial in Toronto (Durvalumab, Oleclumab)

Withdrawn
  • Non Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Durvalumab
  • Oleclumab
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Nov 13, 2020

Resectable, Early-stage, NSCLC Trial in Worldwide (Durvalumab, Oleclumab, Monalizumab)

Completed
Has Results
  • Resectable
  • +2 more
  • La Jolla, California
  • +17 more
Feb 23, 2022

Pancreatic Ductal Adenocarcinoma, NSCLC, Squamous Cell Carcinoma of Head and Neck Trial in Toronto (Durvalumab, Oleclumab)

Withdrawn
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Durvalumab
  • Oleclumab
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Nov 13, 2020

Metastatic NSCLC (NSCLC) Trial in Worldwide (Durvalumab, Danvatirsen, Oleclumab)

Active, not recruiting
  • Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Iowa City, Iowa
  • +45 more
Jan 13, 2023

NSCLC Trial in Worldwide (Durvalumab, Oleclumab, Monalizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • Stuart, Florida
  • +61 more
Dec 19, 2022

Stage III NSCLC, Unresectable Trial in Worldwide (Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab)

Active, not recruiting
  • Stage III Non-small Cell Lung Cancer
  • Unresectable
  • Durvalumab + Oleclumab
  • +2 more
  • Anaheim, California
  • +72 more
Nov 8, 2022

Microsatellite-stable Colorectal Cancer Trial (Standard of Care - mFOLFOX6, E1 - mFOLFOX and durvalumab, E2 - mFOLFOX6,

Withdrawn
  • Microsatellite-stable Colorectal Cancer
  • Standard of Care - mFOLFOX6
  • +3 more
  • (no location specified)
Sep 17, 2020

Advanced Solid Malignancies Trial in Chuo-ku (MEDI9447 (oleclumab))

Completed
  • Advanced Solid Malignancies
  • MEDI9447 (oleclumab)
  • Chuo-ku, Japan
    Research Site
Jul 4, 2019

NSCLC Trial in Worldwide (Durvalumab, Oleclumab, Monalizumab)

Recruiting
  • Non-Small Cell Lung Cancer
  • San Diego, California
  • +197 more
Oct 11, 2022

NSCLC Trial in Worldwide (Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Dacomitinib (PF-00299804)
  • +3 more
  • Birmingham, Alabama
  • +223 more
Apr 24, 2017